Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality10/10

US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:17 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Historically, FDA rejections have led to significant stock price declines. Similar cases saw drops up to 30% immediately after such news.

AI summary

What happened, with direct paths to the underlying reporting

FDA declined approval for Scholar Rock's drug due to manufacturing issues. Third-party facility problems hindered drug approval for a rare disease.

FDA declined approval for Scholar Rock's drug due to manufacturing issues.
Third-party facility problems hindered drug approval for a rare disease.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

US FDA declines to approve Scholar Rock's muscle weakness drug

Scholar Rock advances apitegromab path with alternate fill-finish and PMDA alignment

EU decision on SRRK SMA therapy delayed as FDA facility classification awaits

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth